Transcode Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Transcode Therapeutics Inc 's ROA in the second quarter of 2026?
Transcode Therapeutics Inc recorded a cumulative net loss of $-43 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -35.69%.

However, within the Healthcare sector 463 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3906, from total ROA ranking in the first quarter of 2026 at 4820.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	1754.07 %	1091.15 %	1908.64 %	91.68 %	81.17 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-43	-40	-35	-27	-25
Return On Assets (TTM)	-35.69 %	-48.18 %	-72.54 %	-295.25 %	-295.57 %
RNAZ's Total Ranking	# 3906	# 4820	# 4694	# 4755	# 4846
Total Assets (TTM) in million	153	157	162	7	8
Seq. Total Assets Change	-2.48 %	-3.22 %	2137.89 %	-12.21 %	-37.35 %
Seq. Net Income Change	-	-	-	-	-

RNAZ's 5 Years Annual ROA >> Back to RNAZ Management Effectiveness >> Compare RNAZ ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 183
Sector	# 464
Overall	# 3709

Return On Assets Statistics
High	Average	Low
-20.21 %	-182.65 %	-349.33 %
(Mar 31 2022)		(Mar 31 2025)

News about Transcode Therapeutics Inc Return on Assets ROA

Pioneering Advances in RNA Therapeutics TransCode Therapeutics Initiates Phase 1 Clinical Trial for Novel Lead Cand...

: TransCode Therapeutics has announced the successful initiation of its Phase 1 clinical trial, marking a significant milestone in the field of RNA-based therapeutics. This trial explores the safety and efficacy of the company’s first-in-class lead therapeutic candidate, TTX-MC138, designed for the treatment of cancer that expresses miR-10b. This article discusses the implications of this development, the technology behind TransCode s approach, and the potential impact on future cancer therapeutics.The treatment landscape for cancer is continually evolving, with innovative approaches emerging to combat the complexities of tumor biology. TransCode Therapeutics, a biopharmaceutical company specializing in RNA-based therapeutics, recently reported that it has treated its first patients in a Phase 1 clinical trial of its lead therapeutic candidate, TTX-MC138. This trial represents a significant step forward for the company and the field of RNA therapeutics. Background Cancer remains one of the leading causes of mortality worldwide, necessitating urgent advancements in therapeutic strategies. Traditional treatments, including chemotherapy and radiotherapy, often face limitations due to their non-specific targeting and associated side effects. In this context, RNA-based therapeutics offer promising avenues by leveraging the specificity and versatility of RNA molecules to modulate gene expression and target pathological processes at a molecular level.

Navigating Challenges and Opportunities TransCode Therapeutics Secures $2 Million NIH Grant Amid Financia...

TransCode Therapeutics Inc. a clinical-stage biopharmaceutical company focusing on developing RNA-targeted therapeutics for cancer treatment, has recently been awarded a $2 million grant from the National Institutes of Health (NIH). This grant is intended to support the clinical evaluation of TransCode s lead candidate, TTX-MC138, an innovative RNAi-based therapy designed to target the RNA molecules associated with metastatic cancer. Analyzing the NIH GrantReceiving a substantial NIH grant is a strong indicator of the scientific community s confidence in the potential of TransCode Therapeutics’ research. The $2 million grant will be directed towards advancing clinical trials, which are essential for determining the efficacy and safety of TTX-MC138 in human subjects. The scope of the project encompasses various stages of clinical evaluation, which is a crucial step for this candidate to potentially progress to market approval.

Financial Statements
Transcode Therapeutics Inc 's Assets	$ 153 million	RNAZ's Balance sheet
Transcode Therapeutics Inc 's Income	$ -7 million	Quarterly RNAZ's Income Statement
RNAZ's Income by Division		See RNAZ's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	2137.89 %	54.79 %	-38.22 %	-66.92 %	-
Total Assets in million	162	7	5	8	23
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-35	-17	-19	-18	-7
Annual Return On Assets	-21.34 %	-231.31 %	-395.61 %	-231.48 %	-29.83 %

RNAZ's 5 Years Annual ROA >> Back to RNAZ Management Effectiveness >> Compare RNAZ ROA to its Competitors

More Return On Assets Ratios
RNAZ's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RNAZ's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RNAZ's Competitors
Subscribers only: Roa for Transcode Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for RNAZ's Customers

You may also want to know
RNAZ's Roi	RNAZ's Inventory Turnover Ratio	RNAZ's Growth Rates	RNAZ's Dividend Comparisons
	RNAZ's Profitability Ratios	RNAZ's Asset Turnover Ratio	RNAZ's Dividend Growth
RNAZ's Roe	RNAZ's Valuation Ratios	RNAZ's Financial Strength Ratios	RNAZ's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-15T07:34:16+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.